AC
PBYI icon

AXQ Capital’s Puma Biotechnology PBYI Stock Holding History

AXQ Capital’s Portfolio PBYI Stock Details PBYI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,592
Closed -$98.7K – 1203
2025
Q4 		$98.7K Buy
+16,592
New +$88.1K 0.02% 653

Other funds holding PBYI

ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

AXQ Capital's PBYI Position: Q1 2026 in Review

AXQ Capital sold out of Puma Biotechnology (PBYI) in Q1 2026, closing a stake of 16,592 shares — an estimated $98.7K sold.

AXQ Capital first reported a position in PBYI in Q4 2025 and held it in 1 quarter. The position peaked at $98.7K in Q4 2025. 157 funds tracked by Wall St. Rank hold PBYI as of Q1 2026.

  • AXQ Capital reported no remaining Puma Biotechnology position as of Q1 2026 after selling out during the quarter.
  • AXQ Capital sold 16,592 Puma Biotechnology shares in Q1 2026, an estimated $98.7K.
  • AXQ Capital first reported a position in Puma Biotechnology in Q4 2025 and held it in 1 quarter.
  • AXQ Capital's Puma Biotechnology position peaked at $98.7K in Q4 2025.
  • 157 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2026.

Based on AXQ Capital's 13F filing for Q1 2026, filed 13 May 2026.